Indivior Pharmaceuticals, Inc. filed a current report on October 29, 2026, disclosing its financial results for the quarter and nine months ended September 30, 2026, and providing an update on its pending merger with Supernus Pharmaceuticals, Inc.

Key Highlights

  • Record quarterly SUBLOCADE net revenue: Total SUBLOCADE net revenue reached $267 million in Q3 2026, up 22% year-over-year from $219 million.
  • Total net revenue up 13%: Quarterly total net revenue was $356 million, compared to $314 million in Q3 2025.
  • Record quarterly net income: GAAP net income for Q3 2026 was $137 million, or $1.12 diluted earnings per share, versus $42 million, or $0.33 diluted EPS, in Q3 2025.
  • Record adjusted EBITDA: Adjusted EBITDA for Q3 2026 was $211 million, up 76% year-over-year from $120 million.
  • Cash and investments: The company ended Q3 2026 with cash and investments of $332 million, according to the filing.
  • Merger expected to close November 2, 2026: Indivior shareholders approved the proposed merger with Supernus; the combined company is expected to trade on Nasdaq under the ticker symbol "SUPN" beginning November 3, 2026.
  • Over 583,000 patients prescribed SUBLOCADE: As of September 30, 2026, more than 583,000 patients in the U.S. have been prescribed SUBLOCADE since launch, the filing states.

Indivior Q3 2026 Financial Results and Supernus Merger Update

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) reported third-quarter 2026 financial results via a current report filed October 29, 2026. According to the filing, total net revenue for the quarter ended September 30, 2026 was $356 million, a 13% increase compared to $314 million in the prior-year quarter. Total SUBLOCADE net revenue reached $267 million, up 22% year-over-year, with U.S. SUBLOCADE net revenue increasing 24% to $252 million, "primarily driven by 17% dispense unit volume growth," as stated in the filing. Net revenue also benefited from "more favorable price/mix and gross-to-net adjustments," according to the press release.

The company reported GAAP net income of $137 million ($1.12 diluted EPS) for Q3 2026, compared to $42 million ($0.33 diluted EPS) in Q3 2025. Non-GAAP net income was $161 million ($1.32 diluted EPS), versus $93 million ($0.72 diluted EPS) in the year-ago quarter. GAAP operating expenses declined 33% year-over-year to $125 million, while Non-GAAP operating expenses fell 29% to $103 million, according to the filing. Adjusted EBITDA margin was reported at 59%, up 2,100 basis points year-over-year.

For the nine months ended September 30, 2026, the filing discloses total net revenue of $1,016 million, up 15% from $881 million in the same period of 2025, and total SUBLOCADE net revenue of $753 million, up 25% from $604 million. GAAP net income for the nine-month period was $348 million ($2.78 diluted EPS). The company also disclosed full-year 2026 standalone guidance, including net revenue of $1,295 million to $1,365 million and adjusted EBITDA of $700 million to $740 million, noting this guidance will no longer apply upon completion of the merger. The filing states the merger is expected to close November 2, 2026, after which the combined company will operate as Supernus, Inc.

What Was Disclosed

Indivior Pharmaceuticals filed its Q3 2026 financial results, reporting record SUBLOCADE net revenue, record quarterly net income, and record adjusted EBITDA for the quarter ended September 30, 2026, along with an update on the pending all-stock merger with Supernus Pharmaceuticals.